Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

10.0%

1 terminated out of 10 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

9Total
Not Applicable (1)
Early P 1 (4)
P 1 (4)

Trial Status

Recruiting6
Not Yet Recruiting2
Withdrawn1
Terminated1

Clinical Trials (10)

Showing 10 of 10 trials
NCT07085676Phase 1Recruiting

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

NCT06913608Phase 1Withdrawn

A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases

NCT06462144Early Phase 1Terminated

IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy

NCT07086404Early Phase 1RecruitingPrimary

GC012F Injection in Refractory Idiopathic Inflammatory Myopathy

NCT06614270Not ApplicableRecruiting

Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases

NCT07229144Phase 1Not Yet Recruiting

OM336 in Seropositive Autoimmune Diseases

NCT06888960Early Phase 1Recruiting

Safety Study of CC312 in Autoimmune Disease Patients

NCT07150000Recruiting

Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy

NCT07072884Early Phase 1Not Yet Recruiting

GC012F in Patients With Autoimmune Diseases

NCT06980597Phase 1Recruiting

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases

Showing all 10 trials

Research Network

Activity Timeline